• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    CORRECTION - First Light Acquisition Group, Inc. Transfers Listing to NYSE American LLC

    11/14/22 9:07:08 AM ET
    $FLAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $FLAG alert in real time by email

    NEW YORK, Nov. 14, 2022 (GLOBE NEWSWIRE) -- CORRECTED version from November 14, 2022 5:00 a.m. release. First Light Acquisition Group, Inc. (NYSE:FLAG) ("FLAG"), a special purpose acquisition company, announced today that it will transfer its listing to the NYSE American LLC ("NYSE American"), where it has been approved to list. In connection with the transfer, FLAG will voluntarily delist from The New York Stock Exchange. FLAG's decision to transfer to the NYSE American was motivated by more favorable thresholds for continued listing on the NYSE American following recent redemptions of FLAG's Class A common stock. Following the transfer, FLAG intends to continue to file the same types of periodic reports and other information it currently files with the Securities and Exchange Commission (the "SEC"). FLAG anticipates the transfer to the NYSE American to occur on or about November 17, 2022.



    For more information, please contact:
    
    FLAG Investor Relations
    [email protected]
    (202) 503-9255

    Primary Logo

    Get the next $FLAG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FLAG

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $FLAG
    SEC Filings

    View All

    First Light Acquisition Group Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

    2/12/24 6:30:32 AM ET
    $FLAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B3 filed by First Light Acquisition Group Inc.

    424B3 - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

    2/12/24 6:32:40 AM ET
    $FLAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    First Light Acquisition Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

    8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

    2/7/24 1:06:39 PM ET
    $FLAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FLAG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Zulueta Alfonso G was granted 5,644 shares, increasing direct ownership by 4% to 133,301 units (SEC Form 4)

    4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

    1/4/24 7:55:27 PM ET
    $FLAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Stewart Alan R. was granted 7,282 shares, increasing direct ownership by 15% to 54,655 units (SEC Form 4)

    4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

    1/4/24 7:52:55 PM ET
    $FLAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Schoeneck James A was granted 10,625 shares, increasing direct ownership by 62% to 27,872 units (SEC Form 4)

    4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

    1/4/24 7:51:34 PM ET
    $FLAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FLAG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies

    Business combination transaction with First Light Acquisition Group, a special purpose acquisition company, completed on September 12, 2023 Gross proceeds made available to Calidi Biotherapeutics from transaction total approximately $28 million, including funds held in First Light Acquisition Group's trust account before deducting transaction expenses and debt repayments In addition, Calidi secured a forward purchase agreement for up to $10 million with a consortium including Meteora Capital LLC, Great Point Capital LLC, and Funicular Funds, LP and intends to enter into a purchase agreement with Lincoln Park Capital Fund, LLC for up to $50 million; proceeds to extend Calidi's cash runway

    9/13/23 5:50:00 AM ET
    $FLAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    First Light Acquisition Group Announces NYSE Approval for Listing of Business Combination with Calidi Biotherapeutics and Additional New Capital Commitments

    Business combination transaction with Calidi Biotherapeutics anticipated to be completed on September 12, 2023 Gross proceeds made available to Calidi Biotherapeutics from transaction will total approximately $28 million, including funds held in First Light Acquisition Group's trust account before deducting transaction expenses and debt repayments In addition, Calidi secured a forward purchase agreement for up to $10 million with a consortium including Meteora Capital LLC, Great Point Capital LLC, and Funicular Funds, LP Listed company to be named Calidi Biotherapeutics, Inc. Common stock and warrants approved for listing on the New York Stock Exchange American under the ticker symbols

    9/11/23 4:05:40 PM ET
    $FLAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FIRST LIGHT ACQUISITION GROUP, INC. Adjourns Special Meeting of Stockholders to August 24, 2023 at 10:30 am ET

    NEW YORK, Aug. 22, 2023 (GLOBE NEWSWIRE) -- First Light Acquisition Group, Inc. (NYSE:FLAG) ("FLAG") today announced that it convened and then adjourned, without conducting any other business, its virtual Special Meeting of Stockholders to August 24, 2023 at 10:30 a.m., Eastern time (the "Special Meeting"). The adjourned Special Meeting will be held via the same live webcast at https://www.cstproxy.com/firstlightacquisition/2023. The Special Meeting is being held to consider and vote on, among other things, the business combination transaction between FLAG and Calidi Biotherapeutics, Inc. ("Calidi"), pursuant to an Agreement and Plan of Merger, dated January 9, 203, as amended, by and amo

    8/22/23 11:41:05 AM ET
    $FLAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FLAG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by First Light Acquisition Group Inc. (Amendment)

    SC 13G/A - Calidi Biotherapeutics, Inc. (0001855485) (Subject)

    2/14/24 4:02:35 PM ET
    $FLAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by First Light Acquisition Group Inc. (Amendment)

    SC 13G/A - Calidi Biotherapeutics, Inc. (0001855485) (Subject)

    2/14/24 6:05:50 AM ET
    $FLAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by First Light Acquisition Group Inc. (Amendment)

    SC 13G/A - Calidi Biotherapeutics, Inc. (0001855485) (Subject)

    2/12/24 5:32:10 PM ET
    $FLAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care